CO6650338A2 - Antígenos de tuberculosis modificados - Google Patents

Antígenos de tuberculosis modificados

Info

Publication number
CO6650338A2
CO6650338A2 CO12125075A CO12125075A CO6650338A2 CO 6650338 A2 CO6650338 A2 CO 6650338A2 CO 12125075 A CO12125075 A CO 12125075A CO 12125075 A CO12125075 A CO 12125075A CO 6650338 A2 CO6650338 A2 CO 6650338A2
Authority
CO
Colombia
Prior art keywords
modified
antigens
medicines
prevention
modified rv3616c
Prior art date
Application number
CO12125075A
Other languages
English (en)
Inventor
Normand Blais
James E Brown
Anne Marie Gelinas
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biolog Sa
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Glaxo Group Ltd filed Critical Glaxosmithkline Biolog Sa
Publication of CO6650338A2 publication Critical patent/CO6650338A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Proteínas Rv3616c modificadas y su uso como medicamentos, en particular para la prevención de la reactivación de tuberculosis.
CO12125075A 2010-01-27 2012-07-25 Antígenos de tuberculosis modificados CO6650338A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29871010P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
CO6650338A2 true CO6650338A2 (es) 2013-04-15

Family

ID=44318698

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12125075A CO6650338A2 (es) 2010-01-27 2012-07-25 Antígenos de tuberculosis modificados

Country Status (24)

Country Link
US (2) US8932600B2 (es)
EP (1) EP2528621B1 (es)
JP (2) JP6010463B2 (es)
KR (1) KR20120129927A (es)
CN (1) CN102869372B (es)
AU (1) AU2011209399B2 (es)
BR (1) BR112012018669A2 (es)
CA (1) CA2786969C (es)
CO (1) CO6650338A2 (es)
CY (1) CY1119518T1 (es)
DK (1) DK2528621T3 (es)
EA (1) EA201290590A1 (es)
ES (1) ES2614266T3 (es)
HR (1) HRP20161608T1 (es)
HU (1) HUE031184T2 (es)
LT (1) LT2528621T (es)
MX (1) MX2012008790A (es)
MY (1) MY156697A (es)
PL (1) PL2528621T3 (es)
PT (1) PT2528621T (es)
SG (1) SG182573A1 (es)
SI (1) SI2528621T1 (es)
UA (1) UA110103C2 (es)
WO (1) WO2011092253A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2731499C (en) 2008-07-25 2017-01-10 Glaxosmithkline Biologicals S.A. Composition and use thereof for treating or preventing latent tuberculosis
ES2647321T3 (es) 2008-07-25 2017-12-20 Glaxosmithkline Biologicals S.A. Composiciones y procedimientos novedosos
CN106866801A (zh) 2008-07-25 2017-06-20 葛兰素史密丝克莱恩生物有限公司 结核病rv2386c蛋白、组合物及其用途
DK2528621T3 (da) * 2010-01-27 2017-01-02 Glaxosmithkline Biologicals Sa Modificerede tuberkuloseantigener
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013123579A1 (en) * 2012-02-24 2013-08-29 Mcmaster University Adenovirus-based tuberculosis vaccine and its use
CN103467582A (zh) * 2012-06-08 2013-12-25 同济大学 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用
WO2014210018A1 (en) * 2013-06-25 2014-12-31 Aeras Global Tb Vaccine Foundation Tuberculosis compositions and methods of using the same
US10857219B2 (en) 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN105675863B (zh) * 2016-02-17 2017-10-20 遵义医学院附属医院 一组耐多药结核病诊断标志物及其用途
CA3027995A1 (en) 2016-06-16 2017-12-21 Aeras Tuberculosis compositions and methods of treating or preventing tuberculosis
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201618432D0 (en) 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
MX2019006728A (es) 2016-12-07 2019-12-02 Glaxosmithkline Biologicals Sa Nuevo proceso.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
CN109966170B (zh) * 2018-02-13 2022-04-15 深圳高尚科美生物科技有限公司 包含生物大分子的柔性脂质体化妆品及其制备方法
JP2022535091A (ja) 2019-06-05 2022-08-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN116669707A (zh) * 2020-08-05 2023-08-29 杜兰教育基金管理委员会 体液样品中结核的检测方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1786412A (en) * 1929-11-20 1930-12-23 American Telephone & Telegraph Shielding arrangement
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
WO1991012325A1 (en) 1990-02-09 1991-08-22 E.I. Du Pont De Nemours And Company Htlv envelope antigenic segment
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2115554A1 (en) 1991-08-15 1993-03-04 Yves Lobet Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5928647A (en) 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5551622A (en) 1994-07-13 1996-09-03 Yoon; Inbae Surgical stapler
AT402926B (de) 1994-12-05 1997-09-25 Hafslund Nycomed Pharma Heterocyclische amide, verfahren zu ihrer herstellung und verwendung
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
JPH11506332A (ja) 1995-06-02 1999-06-08 インサイト・ファーマスーティカルズ・インコーポレイテッド 全長ｃＤＮＡ配列を獲得する改良された方法
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1997009429A2 (en) 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
TR200806258T2 (tr) 1995-09-01 2008-10-21 Corixa Corporation Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
AU4750597A (en) 1996-10-11 1998-05-11 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6627198B2 (en) 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6350456B1 (en) 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6544522B1 (en) 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
DK1659178T3 (da) 1998-02-05 2010-07-12 Glaxosmithkline Biolog Sa Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
KR100692227B1 (ko) 1998-04-07 2007-03-09 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
CA2386841A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
CA2413959C (en) * 2000-06-20 2015-07-07 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
EP1401866A2 (en) 2001-02-22 2004-03-31 Institut Pasteur Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030175294A1 (en) * 2001-03-13 2003-09-18 Corixa Corporation Heterologous fusion protein constructs comprising a Leishmania antigen
TWI299047B (en) 2002-02-14 2008-07-21 Mitsui Chemicals Inc Polyester resin, catalyst for the production of polyester, process for the production of polyester resin by using the catalyst, and hollow shaped container made from the polyester resin
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
DE60313163T2 (de) * 2002-06-11 2008-01-03 Glaxosmithkline Biologicals S.A. Immunogene zusammensetzungen
US7205259B2 (en) 2002-07-26 2007-04-17 Kimberly-Clark Worldwide, Inc. Absorbent binder desiccant composition and articles incorporating it
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
US7301098B2 (en) 2005-01-19 2007-11-27 Panduit Corp. Communication channels with suppression cores
CA2606962A1 (en) * 2005-04-29 2006-11-09 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
ES2381492T3 (es) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedimiento de prevención o tratamiento de infección por M. tuberculosis
PT1880008E (pt) 2005-05-03 2015-08-27 Inserm Inst Nat De La Santé Et De La Rech Médicale Expressão de proteína mitocondrial através de uma abordagem alotópica melhorada
JP4468858B2 (ja) 2005-06-01 2010-05-26 オリンパスイメージング株式会社 データ符号化装置、データ符号化方法、プログラム
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7296798B2 (en) 2006-01-31 2007-11-20 Matt Overfield Gameboard, games played on board and methods of play requiring strategy and luck
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
US9297803B2 (en) * 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
DK2137210T3 (en) * 2007-03-02 2017-01-30 Glaxosmithkline Biologicals Sa Hitherto unknown method and compositions
GB0716070D0 (en) * 2007-08-17 2007-09-26 Fusion Antibodies Ltd Diagnostic method and kit
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
FR2933552B1 (fr) 2008-07-04 2014-10-10 Centre Nat Rech Scient Circuit d'amplification d'un signal representant une variation de resistance d'une resistance variable et capteur correspondant
CA2731499C (en) * 2008-07-25 2017-01-10 Glaxosmithkline Biologicals S.A. Composition and use thereof for treating or preventing latent tuberculosis
WO2010121618A1 (en) 2009-04-24 2010-10-28 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
WO2011011323A1 (en) 2009-07-21 2011-01-27 Cooper Technologies Company Interfacing a light emitting diode (led) module to a heat sink assembly, a light reflector and electrical circuits
DK2528621T3 (da) * 2010-01-27 2017-01-02 Glaxosmithkline Biologicals Sa Modificerede tuberkuloseantigener
US9119754B2 (en) 2011-10-08 2015-09-01 Michael Dennis Mattress overlay system with positionally adjustable, lateral ramp-wedge bolster structure
US9051890B2 (en) 2013-10-28 2015-06-09 Ford Global Technologies, Llc Method for estimating charge air cooler condensation storage with an intake oxygen sensor
US9903268B2 (en) 2015-04-02 2018-02-27 Ford Global Technologies, Llc Internal combustion engine with two-stage supercharging capability and with exhaust-gas aftertreatment arrangement, and method for operating an internal combustion engine
US9810514B2 (en) 2015-09-08 2017-11-07 Deufol Sunman Inc. Ammunition carrier consumer package

Also Published As

Publication number Publication date
CA2786969A1 (en) 2011-08-04
CY1119518T1 (el) 2018-03-07
UA110103C2 (uk) 2015-11-25
MY156697A (en) 2016-03-15
HRP20161608T1 (hr) 2017-01-13
HUE031184T2 (en) 2017-06-28
DK2528621T3 (da) 2017-01-02
CN102869372B (zh) 2016-01-20
CN102869372A (zh) 2013-01-09
KR20120129927A (ko) 2012-11-28
MX2012008790A (es) 2012-08-17
PL2528621T3 (pl) 2017-07-31
PT2528621T (pt) 2016-12-20
BR112012018669A2 (pt) 2017-09-05
JP2016166193A (ja) 2016-09-15
US8932600B2 (en) 2015-01-13
AU2011209399A1 (en) 2012-08-23
ES2614266T3 (es) 2017-05-30
JP2013517783A (ja) 2013-05-20
EP2528621A1 (en) 2012-12-05
CA2786969C (en) 2018-07-24
EP2528621B1 (en) 2016-09-21
JP6503309B2 (ja) 2019-04-17
SG182573A1 (en) 2012-08-30
JP6010463B2 (ja) 2016-10-19
US20120294882A1 (en) 2012-11-22
WO2011092253A1 (en) 2011-08-04
LT2528621T (lt) 2016-12-12
SI2528621T1 (sl) 2017-01-31
EA201290590A1 (ru) 2013-03-29
US20150093414A1 (en) 2015-04-02
AU2011209399B2 (en) 2014-04-10
US9200044B2 (en) 2015-12-01

Similar Documents

Publication Publication Date Title
CO6650338A2 (es) Antígenos de tuberculosis modificados
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
UY34254A (es) Proteínas y péptidos modificados.
SG195306A1 (en) Purification of biological products by constrained cohydration chromatography
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
TN2014000438A1 (en) Anti-fcrn antibodies
TN2015000050A1 (en) Methods of treating a tauopathy
AR090923A1 (es) Anticuerpos anti-il-23
CR20150048A (es) Anticuerpos e inmunoconjugados anti-cd22
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
UY34885A (es) Proteínas de unión anti-mesotelina
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
ECSP13012446A (es) Ligandos fosfina para reacciones catalíticas
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BR112012018840A2 (pt) proteínas recombinantes para uso em vacina, anticorpos contra as ditas proteínas e métodos de diagnósticos e terapêuticos incluindo as mesmas
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
DE112013002488T8 (de) Vesikuläre Formulierungen, Kits und Verwendungen

Legal Events

Date Code Title Description
FC Application refused